m-dPEG®x- Acid

Amount: 100mg

Item Name: m-dPEG®8-acid

Item #: 10324

Mol. Wt.: 412.47;

single compound dPEG® Spacer is 26 atoms and 29.8 A

Product Features and Benefits: Acid form of the corresponding m-dPEG® NHS esters Can activate the acid in situ using standard activation methods, e.g., with EDC and NHS in methylene chloride (see protocol) Pegylation spacer is water soluble, non-immunogenic and non-toxic, so can be used to modulate the properties of the m-dPEG® pegylation modified compounds. Protocol for in situ activation to the NHS ester: Use a 10-20% molar excess of EDC and NHS in dry methylene chloride (dried over 3A molecular sieves). Add a methylene chloride solution of the acid to the dry reagents under dry conditions. Stir for several hours or overnight, then evaporate the solvent and use. Can also treat reaction mixture with a small amount of silica gel to adsorb the excess EDC and the urea by-product, filter, then evaporate the solvent and use.

Note of caution: The NHS should be added with the EDC to prevent formation of the anhydride. DCC can also be used. Typically use about 1 equivalent, and add a solution of the DCC to the acid and NHS (1.1 to 1.2 equivalents). HOBt or PFP (2,3,4,5,6-pentafluorophenol) could be used in place of the NHS, if this is a preference for the activated ester. Others too can be used as well, but these are probably the most popular. If one wanted to make the sulfo-NHS ester then one would need to use a much more polar solvent in order to accommodate the very poor solubility of the sulfo-NHS in organic solvents, using solvents such as DMF or DMAC.

Amount: 100mg

Item Name: m-dPEG®12-acid

Item #: 10328

Mol. Wt.: 588.68;

single compound dPEG® Spacer is 38 atoms and 44.0 A

Product Features and Benefits: Acid form of the corresponding m-dPEG® NHS esters Can activate the acid in situ using standard activation methods, e.g., with EDC and NHS in methylene chloride (see protocol) Pegylation spacer is water soluble, non-immunogenic and non-toxic, so can be used to modulate the properties of the m-dPEG® pegylation modified compounds. Protocol for in situ activation to the NHS ester: Use a 10-20% molar excess of EDC and NHS in dry methylene chloride (dried over 3A molecular sieves). Add a methylene chloride solution of the acid to the dry reagents under dry conditions. Stir for several hours or overnight, then evaporate the solvent and use. Can also treat reaction mixture with a small amount of silica gel to adsorb the excess EDC and the urea by-product, filter, then evaporate the solvent and use.

Note of caution: The NHS should be added with the EDC to prevent formation of the anhydride. DCC can also be used. Typically use about 1 equivalent, and add a solution of the DCC to the acid and NHS (1.1 to 1.2 equivalents). HOBt or PFP (2,3,4,5,6-pentafluorophenol) could be used in place of the NHS, if this is a preference for the activated ester. Others too can be used as well, but these are probably the most popular. If one wanted to make the sulfo-NHS ester then one would need to use a much more polar solvent in order to accommodate the very poor solubility of the sulfo-NHS in organic solvents, using solvents such as DMF or DMAC.

Amount: 1000mg

Item Name: m-dPEG®16-acid

Item #: 10733

Mol. Wt.: 764.89;

single compound dPEG® Spacer is 50 atoms and 57.9 A

Product Features and Benefits: Acid form of the corresponding m-dPEG® NHS esters Can activate the acid in situ using standard activation methods, e.g., with EDC and NHS in methylene chloride (see protocol) Pegylation spacer is water soluble, non-immunogenic and non-toxic, so can be used to modulate the properties of the m-dPEG® pegylation modified compounds. Protocol for in situ activation to the NHS ester: Use a 10-20% molar excess of EDC and NHS in dry methylene chloride (dried over 3A molecular sieves). Add a methylene chloride solution of the acid to the dry reagents under dry conditions. Stir for several hours or overnight, then evaporate the solvent and use. Can also treat reaction mixture with a small amount of silica gel to adsorb the excess EDC and the urea by-product, filter, then evaporate the solvent and use.

Note of caution: The NHS should be added with the EDC to prevent formation of the anhydride. DCC can also be used. Typically use about 1 equivalent, and add a solution of the DCC to the acid and NHS (1.1 to 1.2 equivalents). HOBt or PFP (2,3,4,5,6-pentafluorophenol) could be used in place of the NHS, if this is a preference for the activated ester. Others too can be used as well, but these are probably the most popular. If one wanted to make the sulfo-NHS ester then one would need to use a much more polar solvent in order to accommodate the very poor solubility of the sulfo-NHS in organic solvents, using solvents such as DMF or DMAC.

Amount: 1000mg

Item Name: m-dPEG®49-acid

Item #: 10928

Mol. Wt.: 2232.65;

single compound dPEG® Spacer is 150 atoms and 177.7 A

Product Features and Benefits: Acid form of the corresponding m-dPEG® NHS esters Can activate the acid in situ using standard activation methods, e.g., with EDC and NHS in methylene chloride (see protocol) Pegylation spacer is water soluble, non-immunogenic and non-toxic, so can be used to modulate the properties of the m-dPEG® pegylation modified compounds. Protocol for in situ activation to the NHS ester: Use a 10-20% molar excess of EDC and NHS in dry methylene chloride (dried over 3A molecular sieves). Add a methylene chloride solution of the acid to the dry reagents under dry conditions. Stir for several hours or overnight, then evaporate the solvent and use. Can also treat reaction mixture with a small amount of silica gel to adsorb the excess EDC and the urea by-product, filter, then evaporate the solvent and use.

Note of caution: The NHS should be added with the EDC to prevent formation of the anhydride. DCC can also be used. Typically use about 1 equivalent, and add a solution of the DCC to the acid and NHS (1.1 to 1.2 equivalents). HOBt or PFP (2,3,4,5,6-pentafluorophenol) could be used in place of the NHS, if this is a preference for the activated ester. Others too can be used as well, but these are probably the most popular. If one wanted to make the sulfo-NHS ester then one would need to use a much more polar solvent in order to accommodate the very poor solubility of the sulfo-NHS in organic solvents, using solvents such as DMF or DMAC.